Dianthus Therapeutics Inc (NAS:DNTH)
$ 22.55 0.81 (3.73%) Market Cap: 661.83 Mil Enterprise Value: 261.52 Mil PE Ratio: 0 PB Ratio: 1.71 GF Score: 20/100

Magenta Therapeutics Inc Definitive Merger Agreement with Dianthus Therapeutics Inc - M&A Call Transcript

May 03, 2023 / 12:30PM GMT
Operator

Good morning, and welcome to today's joint conference regarding the Dianthus Therapeutics and Magenta Therapeutics merger. At this time, all participants are in listen-only mode. Please be advised that the call is being recorded.

Now, I'd like to turn the call over to Steve Mahoney, President and Chief Financial and Operating Officer of Magenta. Please go ahead.

Steve Mahoney
Magenta Therapeutics, Inc. - President, CFO & COO

Thank you, operator, and good morning, everyone. Before I begin, I want to remind everyone that this discussion and the accompanying presentation will contain forward-looking statements based upon the current expectations of Magenta Therapeutics and Dianthus Therapeutics, which include but are not limited to, statements regarding the expected timing, completion, effects, and potential benefits of the transaction and our future expectations, plan and prospects for the combined company, including its projected cash runway.

Such statements represent management's judgment and intention as of today and involve assumptions

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot